Q-omics provides the consensus-scored NFE2L2 profile across patient tissues and cancer cell-line models. NFE2L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NFE2L2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, NFE2L2 RNA expression shows 20,785 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where NFE2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFE2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFE2L2 survival associations across molecular data types. NFE2L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFE2L2 RNA expression–survival associations across cancer types. High NFE2L2 expression shows unfavorable associations in ACC and LGG, but favorable associations in KIRC, LUSC, MESO and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NFE2L2 RNA expression.
This table summarizes NFE2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NFE2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFE2L2 shows lower tumor expression in THCA, KICH, BLCA, LUAD, KIRC and BRCA. The THCA box plot shows higher NFE2L2 RNA expression in normal versus tumor tissue (log2 FC = −0.765, t-test p < 0.001).
This table shows molecular features associated with NFE2L2 in patient tissues and cancer cell lines. In patient samples, NFE2L2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NFE2L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
